COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors.
作者信息
Duan Zhihui, Zhou Shengyun, Sun Xiaofang
机构信息
Department of Endoscopy, Xingtai People's Hospital, Xingtai, Hebei Province, China.
出版信息
Clin Gastroenterol Hepatol. 2022 Jan;20(1):247-248. doi: 10.1016/j.cgh.2021.08.013. Epub 2021 Aug 12.
Abstract
摘要
相似文献
1
COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors.新冠病毒肺炎死亡率：罪魁祸首可能并非质子泵抑制剂。
Clin Gastroenterol Hepatol. 2022 Jan;20(1):247-248. doi: 10.1016/j.cgh.2021.08.013. Epub 2021 Aug 12.
2
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?质子泵抑制剂是病毒感染的风险因素：对新冠病毒感染而言也是如此吗？
Clin Drug Investig. 2020 Oct;40(10):897-899. doi: 10.1007/s40261-020-00963-x.
3
Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy".对“接受质子泵抑制剂治疗的COVID-19患者ACE2水平升高与死亡风险”的回应
Am J Gastroenterol. 2021 Dec 1;116(12):2474. doi: 10.14309/ajg.0000000000001495.
4
An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19.关于质子泵抑制剂作为2019冠状病毒病风险因素的另一种观点
Clin Drug Investig. 2021 Mar;41(3):287-289. doi: 10.1007/s40261-021-01007-8. Epub 2021 Feb 19.
5
Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis.质子泵抑制剂的使用与新型冠状病毒肺炎不良临床结局风险：一项荟萃分析
J Intern Med. 2021 Jan;289(1):125-128. doi: 10.1111/joim.13183. Epub 2020 Oct 20.
6
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort.质子泵抑制剂与重症新型冠状病毒肺炎风险：一项来自韩国全国队列的事后分析
Gut. 2021 Oct;70(10):2013-2015. doi: 10.1136/gutjnl-2020-323672. Epub 2020 Dec 10.
7
Comment on Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.关于质子泵抑制剂使用者中新冠病毒肺炎（COVID-19）风险增加的评论
Am J Gastroenterol. 2020 Nov;115(11):1921. doi: 10.14309/ajg.0000000000001014.
8
Assessment of proton-pump inhibitor use, race, socioeconomic status, and mortality in individuals with COVID-19.对感染新型冠状病毒肺炎（COVID-19）患者使用质子泵抑制剂、种族、社会经济地位及死亡率的评估。
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):239. doi: 10.1097/MEG.0000000000002138.
9
Response to Hajifathalian and Katz Regarding Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors.对哈吉法萨利安和卡茨关于质子泵抑制剂使用者中新冠病毒肺炎（COVID-19）风险增加的回应。
Am J Gastroenterol. 2020 Nov;115(11):1922-1923. doi: 10.14309/ajg.0000000000000993.
10
Proton Pump Inhibitors and Mortality in Individuals With COVID-19.质子泵抑制剂与新冠肺炎患者的死亡率
Am J Gastroenterol. 2020 Nov;115(11):1918. doi: 10.14309/ajg.0000000000000992.
本文引用的文献
1
Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.质子泵抑制剂的使用与 SARS-CoV-2 相关结局无显著相关性：一项全国性研究和荟萃分析。
Clin Gastroenterol Hepatol. 2021 Sep;19(9):1845-1854.e6. doi: 10.1016/j.cgh.2021.05.011. Epub 2021 May 11.
2
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study.在英格兰 690 万人中，体重指数与 COVID-19 严重程度的关联：一项前瞻性、基于社区的队列研究。
Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-359. doi: 10.1016/S2213-8587(21)00089-9. Epub 2021 Apr 28.
3
The Unique Impact of COVID-19 on Human Gut Microbiome Research.新冠病毒对人类肠道微生物组研究的独特影响。
Front Med (Lausanne). 2021 Mar 16;8:652464. doi: 10.3389/fmed.2021.652464. eCollection 2021.
4
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.肠道微生物群落组成反映了 COVID-19 患者的疾病严重程度和功能失调的免疫反应。
Gut. 2021 Apr;70(4):698-706. doi: 10.1136/gutjnl-2020-323020. Epub 2021 Jan 11.
5
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis.在 2020 年春季大流行期间估计 SARS-CoV-2 在纽约市的感染病死率：基于模型的分析。
Lancet Infect Dis. 2021 Feb;21(2):203-212. doi: 10.1016/S1473-3099(20)30769-6. Epub 2020 Oct 19.
6
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States.美国11721例2019冠状病毒病（COVID-19）住院患者的特征及预后
Clin Infect Dis. 2021 May 18;72(10):e558-e565. doi: 10.1093/cid/ciaa1268.
Zotero 插件